LONDON--(BUSINESS WIRE)--The primary sclerosing cholangitis treatment market is poised to grow by USD 37.50 million during 2020-2024, progressing at a CAGR of almost 4% during the forecast period. For ...
The MarketWatch News Department was not involved in the creation of this content. Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR ...
DelveInsight’s Primary Biliary Cholangitis Market Insights report includes a comprehensive understanding of current treatment practices, primary biliary cholangitis emerging drugs, market share of ...
LONDON--(BUSINESS WIRE)--The global primary sclerosing cholangitis (PSC) treatment market 2018-2022 is expected to post a CAGR of close to 4% during the forecast period, according to the latest market ...
DelveInsight's,“ Primary Biliary Cholangitis Pipeline Insight 2025 ” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape ...
Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary ...
Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering. This report ...
Please provide your email address to receive an email when new articles are posted on . According to the FDA, primary biliary cholangitis meets the criteria for a rare disease, afflicting fewer than ...
Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback